Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study

Abstract

Objective To evaluate the outcome and safety of the paclitaxel, carboplatin, and capecitabine (TCX) regimen in patients with advanced gastric cancer. Methods Advanced gastric cancer patients received the TCX regimen for up to six cycles, which were 3 weeks apart. Paclitaxel (175 mg/m2) was given over a 3-hour infusion, followed by carboplatin in a 1-hour infusion on day 1. Capecitabine (850 mg/m2) was given orally twice daily from day 1 to day 14. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results Among 83 patients at stage IVa and IVb, the median PFS was 9.3 months; 6-month, 1-year, and 2-year PFS were 74.6%, 32.5%, and 14.4%, respectively. The median OS was 17.0 months; 6-month, 1-year, and 2-year OS were 97.5%, 68.7%, and 21.7%, respectively. In the multivariable Cox regression model, higher CEA was associated with poor OS. Common adverse events included hand-food syndrome (77.9%), peripheral neuropathy (63.2%), fatigue (68.7%), and nausea (54.2%). Conclusion The TCX regimen provided good survival and a better safety profile. More clinical trials are needed to confirm its treatment efficacy and safety, especially in comparison with other triplet regimens.

Dihydromyricetin reverses capecitabine‐induced peripheral myelin dysfunction through modulation of oxidative stress

“…4 Although capecitabine ameliorates 5-Fu-induced adverse effects, recent clinical reports have revealed that capecitabine, both in monotherapy and combined therapy, could induce severe peripheral neuropathy, manifested as numbness, paresthesia, hypoesthesia and even somatization disorders. 5 Based on various clinical trials, the peripheral neuropathy rates caused by capecitabine range from 36% to 73%, 4,6,7 greatly lowering the patients' quality of life. To date, investigations of capecitabineinduced peripheral neurotoxicity have only focused on clinical symptoms without further mechanistic studies.…”

Gastric cancer with brain metastasis: from molecular characteristics and treatment

“…Chemotherapy is one of the conventional treatments for advanced GC patients. Common chemotherapeutic agents include paclitaxel (doxorubicin or paclitaxel), capecitabine, fluorouracil ( 18 ). However, the clinical benefits are limited by the potential risk of injury from surgery, the toxicity of chemotherapeutic agents, and resistance to targeted drugs.…”